Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bio-Rad Laboratories reports robust earnings, eyes growth through new products

Bio-Rad Laboratories showcased strong financial performance, operational improvements, and strategic initiatives during the Q4 2022 earnings call. Despite challenges like supply chain disruptions and margin impacts, the company remains optimistic about its growth prospects and commitment to long-term targets.

Bio-Rad reports resilient Q1 performance amidst challenges and opportunities

Bio-Rad Laboratories navigated challenges in Q1 2023 to achieve core sales growth and solid non-GAAP net income, with a revised 2023 outlook projecting 4.5% revenue growth.
The impact of Russian sanctions and margin improvement plans were key discussion points, alongside the company's focus on expense management and operational transformation.
With a strategic approach to growth, strong performance in key business segments, and a focus on operational efficiency, Bio-Rad aims to capitalize on opportunities for expansion and resilience.

Bio-Rad reports Q2 earnings decline, eyes ddPCR growth opportunities

Bio-Rad Laboratories faced challenges in BioPharma but showed strengths in Clinical Diagnostics and Life Science segments.
Despite a decline in net sales, the company reported strong demand for ddPCR and authorized a new share repurchase program.
Anticipated challenges in BioPharma and China may impact revenue growth, but opportunities exist in expanding ddPCR sales and cost-saving measures.
The company maintains a strong cash position, views its valuation favorably, and plans to participate in upcoming healthcare conferences.

Bio-Rad Labs faces Q3 challenges, eyes ddPCR market growth

Bio-Rad Laboratories faced challenges in Q3 2023 due to biopharma segment issues and economic constraints in China, impacting revenue and forecasting.
Despite weaknesses, the company saw growth in Clinical Diagnostics revenue and remains focused on operational transformation and strategy execution.
Analysts raised concerns about market dynamics and share losses, while Bio-Rad plans to address challenges and capitalize on opportunities in the ddPCR market.
The company anticipates a strong Q4 to offset Q3 challenges and is prepared for potential macroeconomic impacts on biotechnology spending.

Bio-Rad Labs reports Q4 revenue decline, eyes growth opportunities

Bio-Rad Laboratories navigated challenges in Q4 2023, with revenue declines but operational resilience in key segments.
The company faces headwinds in the China market but sees opportunities in new product launches and market recovery.
Financial stability is evident with strong cash reserves, while strategic adjustments are needed to drive future growth.
Guidance for 2024 hints at a potential turnaround, with a focus on operational efficiency and revenue expansion.

Bio-Rad Laboratories reports mixed Q1 performance, maintains outlook optimism

Bio-Rad Laboratories' Q1 2024 earnings call highlighted a mixed performance with declines in Life Science sales but growth in Clinical Diagnostics. Despite challenges in certain segments, the company maintains its full-year outlook and is optimistic about long-term growth strategies and market trends.

Bio-Rad Laboratories reports solid Q2 performance amidst global spending constraints

Bio-Rad Laboratories had a solid quarter but revised full-year outlook due to global spending constraints.
Operational improvements and successful share repurchases demonstrate resilience and strategic focus.
Challenges in the Life Science group highlight areas for improvement and strategic decision-making.

Bio-Rad Laboratories exceeds revenue targets in Q3 2024 earnings call

Bio-Rad Laboratories reported a strong Q3 performance with revenue surpassing targets driven by product mix and cost efficiencies.
While facing challenges in certain segments, opportunities lie in the expected return to growth in 2025 and the expansion of the Droplet Digital PCR franchise.
Maintained revenue guidance for 2024 with margin improvements and a focus on corporate transformations and acquisitions for future growth.
Analyst questions during the call covered a range of topics including margins, market dynamics, and product pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $3 per share, beating the Zacks Consensus Estimate of $2.55 per share. This compares to earnings of $3.38 per share a year ago.

Bio-Rad Laboratories (BIO) Tops Q2 Earnings Estimates

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023. Second-quarter 2023 net sales were $681.1 million, a decrease of 1.4 percent compared to $691.1 million reported for the second quarter of 2022. On a currency-neutral basis, quarterly sales decreased 0.3 percent compared to the same period in 2022. COVID-related.

Bio-Rad Reports Second-Quarter 2023 Financial Results

QIAGEN

HERCULES, Calif., & VENLO, the Netherlands--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology. The settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each co.

Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement

Bio-Rad Laboratories' (BIO) second-quarter 2023 results are likely to reflect an impressive performance across its Clinical Diagnostics business.

Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding shares of its common stock. “The new share buyback authorization is consistent with our disciplined approach and demonstrates our continued commitment to using this tool as p.

Bio-Rad Announces New Share Repurchase Program

APA Corporation

Caesars Entertainment

Enphase Energy

Etsy

Halliburton

Moderna

SolarEdge Technologies

Warner Bros Discovery Inc

Analysts have the typical hopes for the S&P 500 in the next 12 months. But they're especially bullish on a small handful of stocks.

10 Stocks Will Make You 30% Richer Than Others In A Year, Analysts

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2023 on Thursday, August 3, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, call 888-259-6580 within the U.S., access code: 94809387. From outside the.

Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its corporate sustainability report for fiscal year ended December 31, 2022. The report has been prepared with reference to the Global Reporting Initiative (GRI) 2021 Standards and in alignment with the Sustainability Accounting Standards Board (SASB). It provides an update on Bio-Rad's progress towards achieving its long-t.

Bio-Rad Publishes Corporate Sustainability Report for 2022

Alaska Air Group

Alexandria Real Estate Equities

Axon Enterprise

Delta Air Lines

Jacobs Solutions Inc

Schlumberger

Targa Resources

Vici Properties

Analysts rarely agree on much. So when they do — especially on the best S&P 500 stocks to buy — it's worth hearing them out.

Analysts Are Almost 100% Certain You Should Buy These 10 Stocks

Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.

Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, will present a company overview at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3 PM Eastern Time. The presentation will be followed by a Q&A session with participation from Bio-Rad's Executive Vice President and CFO Ilan Daskal. A link to a live webcast and.

Bio-Rad to Present Company Overview at Jefferies Healthcare Conference

Bio-Rad previously experienced a significant jump in sales due to Covid-19 testing. However, with Covid-related sales falling off, the overall revenue has also been reduced in 2022.

Bio-Rad And Its Real Value

Accolade

Quest Diagnostics

Sangamo Therapeutics

Sotera Health

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May - Bio-Rad Laboratories (NYSE:BIO), Accolade (NASDAQ:ACCD)

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company's management will participate in a fireside chat event during the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 3:35 PM Eastern Time (12:35 PM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-R.

Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference

Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.

Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Ed Chung - Vice President, Investor Relations Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Simon May - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Patrick Donnelly - Citi Dan Leonard - Credit Suisse Jack Meehan - Nephron Research Operator Good afternoon. Thank you for attending the Bio-Rad First Quarter 2023 Earnings Conference Call.

Bio-Rad Laboratories, Inc. (BIO) Q1 2023 Earnings Call Transcript

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.24 per share. This compares to earnings of $4.94 per share a year ago.

Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2023. First-quarter 2023 net sales were $676.8 million, a decrease of 3.3 percent compared to $700.1 million reported for the first quarter of 2022. On a currency-neutral basis, quarterly sales decreased 0.3 percent compared to the same period in 2022. COVID-related s.

Bio-Rad Reports First-Quarter 2023 Financial Results

Here is how Bio-Rad Laboratories (BIO) and GSK (GSK) have performed compared to their sector so far this year.

Are Medical Stocks Lagging BioRad Laboratories (BIO) This Year?

Bio-Rad (BIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bio-Rad Laboratories (BIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Henry Schein

Insulet

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.

3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings

Bio-Rad Laboratories' (BIO) first-quarter 2023 results are likely to reflect an impressive performance across its Life Science segment, with a gradual reduction in backlogs and an improvement in the supply chain.

BioRad Laboratories (BIO) to Post Q1 Earnings: What's in Store?

Investors are optimistic about Bio-Rad's (BIO) strong global presence and stable solvency position.

Bio-Rad (BIO) Rises 6.5% Since Q4 Earnings: What's Driving It?

Here is how Bio-Rad Laboratories (BIO) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.

Is BioRad Laboratories (BIO) Stock Outpacing Its Medical Peers This Year?

Bio-Rad is back on the table as an attractive value proposition once again. The firm is well-positioned to unlock tremendous value for shareholders looking ahead, in my estimation. Profitability is a standout, and the Sartorius equity position is an embedded source of alpha.

News for Bio-Rad Laboratories Stock (BIO)